
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 30 years ago
Calcium Channel Blockers: 1995 - An Overviewover 30 years ago
Safety of Calcium Channel Blockers: Results of Recent Trialsover 30 years ago
Calcium Channel Blockers: New Trials and Trials in Progressover 30 years ago
Are Calcium Channel Blockers Prohemorrhagic?over 30 years ago
Shades of Opinion: What Is Prudent?over 30 years ago
Participants





